Beam Therapeutics Inc.’s base editing platform with BEAM-101 has trait-like hematology and RMAT/ODD designations. BEAM thinks this could eventually position it with a potential best-in-class SCD drug.
Beam Therapeutics' pipeline progress remains slow, with BEAM-101 still recruiting and CAR-T programs discontinued to reduce cash burn. Gene therapy markets targeted by Beam, such as SCD and AATD, are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback